| Hans-Günter Meyer-Thompson | Buprenorphin
Buprenorphine. New long-lasting implant to treat opioid dependence
Buprenorphine. New long-lasting implant to treat opioid dependence
EMA’s human medicines committee (CHMP) has recommended granting a marketing authorisation in the European Union (EU) for Sixmo (buprenorphine) as a substitution treatment for opioid dependence.
Sixmo is an implant that releases low levels of buprenorphine into the patient’s body for six months. It is indicated in clinically stable adult patients who require no more than 8 mg per day of sublingual (i.e. administered under the tongue) buprenorphine, within a framework of medical, social and psychological treatment. (EMA - European Medicines Agency, Amsterdam, 26.04.2019)
https://www.ema.europa.eu/en/news/new-long-lasting-implant-treat-opioid-dependence